Angiotensin II receptor antagonists in chronic heart failure: Where do they fit?

Drugs

Volumn 62, Issue 10, 2002, Pages 1433-1440

  Houghton, Andrew R ^a  

^a United Lincolnshire Hospitals NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; LISINOPRIL; LOSARTAN; SARALASIN; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOLERABILITY; HEART FAILURE; HEMODYNAMICS; HUMAN; MEDIATOR RELEASE; MORBIDITY; MORTALITY; PHARMACOLOGICAL BLOCKING; PROGNOSIS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASODILATATION;

EID: 0036070853     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262100-00001     Document Type: Review

References (56)

1. Effects of enalapril on mortalily in severe congestive heart failure: Results of the cooperative north scandinavian enalapril survival study (CONSENSUS)
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
3. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
4. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure
5. Regional hemodynamic effects of perindopril in congestive heart failure
6. Neurohormonal activation and congestive heart failure: Today's experience with ACE inhibitors and rationale for their use
7. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
8. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
9. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
10. Long term survival in severe heart failure in patients treated with enalapril: Ten year follow up of CONSENSUS I
11. Randomised trial of losartan versus captopril in patients over 65 with heart failure: Evaluation of losartan in the elderly study, ELITE
12. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure
13. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the losartan heart failure survival study - ELITE II
14. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
15. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design
16. Comparison of baseline data, initial course, and management: Losartan versus captopril following acute myocardial infarction (the OPTIMAAL trial)
17. The effects of spironolactone on morbidity and mortality in patients with severe heart failure
18. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
19. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD pilot study investigators
20. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
21. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil
22. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure
23. Valsartan in acute myocardial infarction trial - VALIANT: Rationale and design
24. Angiotensin II-forming pathways in normal and failing human hearts
25. Progression of left ventricular dysfunction during enalapril therapy: Relationship with neuro-hormonal reactivation
26. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure
27. The positive association of cough with angiotensin-converting enzyme inhibitors
28. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: The design of a prospective, controlled study
29. Angiotensin converting inhibitors and the allergist
30. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathoghysiology
31. Cough and inhibition of the renin-angiotensin system
32. Bradykinin-mediated effects of ACE inhibition
33. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm
34. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
35. Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men
36. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure
37. Angiotensin II receptors and angiotensin II receptor antagonists
38. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
39. Cardiac-specific over-expression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects
40. Angiotensin II receptor antagonists
41. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
42. Losartan in heart failure: Hemodynamic effects and tolerability
43. Valsartan in heart failure patients previously untreated with an ACE inhibitor
44. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
45. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
46. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure
47. Improved exercise tolerance after losartan and enalapril in heart failure: Correlation with changes in skeletal muscle myosin heavy chain composition
48. Effects of modulators of the renin-angiotensin-aldosterone system on cough
49. Angioedema induced by the angiotensin II blocker losartan
50. Angioneurotic edema attributed to the use of losartan
51. Plasma bradykinin in angio-oedema
52. Combined heart failure treatment with ACE inhibition and ATI-receptor blockade
53. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
54. Addition of anglotensin II receptor blockade to maximal anglotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
55. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
56. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?